TrialNature communications2025

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.

Matthew P Morrow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.